Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurosense Therapeutics Ltd (NRSN)

Neurosense Therapeutics Ltd (NRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,994
  • Shares Outstanding, K 13,670
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,210 K
  • EBIT $ -3 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +908,281.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8930 +31.02%
on 11/13/25
1.2700 -7.87%
on 11/19/25
+0.1200 (+11.43%)
since 11/05/25
3-Month
0.8930 +31.02%
on 11/13/25
1.9800 -40.91%
on 09/10/25
-0.0100 (-0.85%)
since 09/05/25
52-Week
0.8100 +44.44%
on 12/16/24
2.6000 -55.00%
on 06/12/25
+0.1300 (+12.50%)
since 12/05/24

Most Recent Stories

More News
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

CAMBRIDGE, Mass. , Dec. 4, 2025 /PRNewswire/ --  NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSNW : 0.3446 (unch)
NRSN : 1.1700 (-2.50%)
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSN : 1.1700 (-2.50%)
NeuroSense to Host Investor Webinar on December 8, 2025

Business, regulatory and clinical updates will be provided

NRSNW : 0.3446 (unch)
NRSN : 1.1700 (-2.50%)
Neurosense Therapeutics Ltd. (NRSN) Receives a New Rating from Noble Financial

Neurosense Therapeutics Ltd. received a Buy rating and a $9.00 price target from Noble Financial analyst Robert LeBoyer on October 14. The company’s shares closed yesterday at $1.24.Elevate Your Investing...

NRSN : 1.1700 (-2.50%)
NeuroSense Announces Promising Alzheimer’s Biomarker Reductions with PrimeC

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Neurosense...

NRSN : 1.1700 (-2.50%)
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

CAMBRIDGE, Mass. , Oct. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSN : 1.1700 (-2.50%)
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile

NRSN : 1.1700 (-2.50%)
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Financing at 40% premium to market price provides near-term bridge to anticipated milestones

NRSN : 1.1700 (-2.50%)
NeuroSense Provides Business Update and Progress for the First Half of 2025

CAMBRIDGE, Mass. , July 31, 2025 /PRNewswire/ --  NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments...

NRSN : 1.1700 (-2.50%)
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Live Broadcast: Award-Winning Actor & ALS Advocate Aaron Lazar hosts NeuroSense CEO Alon Ben-Noon to Unveil New Insights into NeuroSense's Breakthrough Science, Canadian Regulatory Milestones &...

NRSN : 1.1700 (-2.50%)

Business Summary

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company. It focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, such as ALS, Alzheimer's and Parkinson's disease. NeuroSense Therapeutics Ltd. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.3633
2nd Resistance Point 1.2967
1st Resistance Point 1.2333
Last Price 1.1700
1st Support Level 1.1033
2nd Support Level 1.0367
3rd Support Level 0.9733

See More

52-Week High 2.6000
Fibonacci 61.8% 1.9162
Fibonacci 50% 1.7050
Fibonacci 38.2% 1.4938
Last Price 1.1700
52-Week Low 0.8100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar